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1. The Fuster-CNIC-Ferrer CV Polypill: making the leap from 
conceptual debate to worldwide reality
Moving from the theoretical proposal of a CV polypill to 
the actual pharmaceutical development of a combination pill 
presents several challenges. The selection of the medications 
to include in the combination pill is a complex process. Wald 
and Law suggested a pill composed of 6 different compounds 
in order to maximize potential benefit [1]. Although the idea 
of combining so many compounds into a single pill may seem 
attractive for some patient populations, the reality is that the 
difficulty of manufacturing a combination pill increases with each 
component due to challenges related to the chemical properties 
of each substrate (Figure 1). The concept of a CV polypill for 
secondary prevention proposed by Fuster et al. resulted from 
having a clear picture of the global burden of cardiovascular 
disease (CVD) [2]. The effectiveness of the drugs included in a 
polypill are generally well understood, and the principles behind 
using pharmacotherapy at a population level are that the drugs 
themselves should have a well-known risk/benefit ratio and 
should be supported by an evidence-based efficacy and safety in 
secondary CV prevention. On the other hand, a polypill is simple 
to administer and is an effective option to increase adherence in 
order to reduce CV events on top of the promotion of lifestyle 
changes for multiple risk factor control [3].
The Fuster-CNIC-Ferrer CV polypill (commercialized under 
Trinomia®, Sincronium® and Iltria® brand names) was developed 
within a very clear conceptual framework: to provide 
accessibility of treatment to as many patients worldwide for the 
longest periods of time so as to prevent recurrence of events and 
death, by simplifying treatment in a cost effective way [2,4]. At 
the core of this concept lies the decision of including guideline 
recommended therapy for secondary prevention, namely, 
blood pressure control and prevention of the LV remodeling 
process that accompanies cardiac dysfunction after myocardial 
infarction (MI), cholesterol lowering, plaque stabilization and 
use of antiplatelet drugs to prevent further CVD events, all of 
which are known to be effective in secondary prevention [5,6]. 
From a clinical standpoint, each additional drug presents the 
possibility for more adverse effects (AEs) and thus using too 
many components could limit the potential patient population. 
Furthermore, when choosing the components of the pill, the 
target population of the therapy must be considered because 
the benefit for some of the drugs varies with respect to use in 
primary and secondary prevention of CVD. For example, a polypill 
that targets secondary prevention might favor the inclusion of 
an antithrombotic agent, a statin and blood pressure lowering 
agents (an angiotensin-converting enzyme (ACE) inhibitor and 
beta-blocker (BB) over a calcium channel blocker (CCB)) given 
the known mortality benefit of the former medications in post-
MI patients. The Fuster-CNIC-Ferrer CV polypill does not include 
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During the last decade, there has been a tremendous effort to develop different cardiovascular 
polypills in response to the upsurge in global cardiovascular disease worldwide. The pharmacological 
development of such a strategy has proven to be extremely complex from a formulation standpoint. 
Not all drugs are suitable for use in a polypill because of potential drug incompatibilities between them. 
Candidate agents must be safe, well tolerated, effective, guideline recommended and physiochemically 
compatible with the other components of the pill.
The Fuster-CNIC-Ferrer cardiovascular (CV) polypill has been found to be the first-in-class polypill to 
be approved and commercialized in Europe and Latinamerican Countries. In this article, we review the 
pharmacological properties of its three components, including the clinical evidence supporting their 
use in patients with established cardiovascular disease, their pharmacokinetic properties, adverse 
effects, drug interactions and contraindications.
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a BB in their combination pill, based on clinical and technical 
aspects. Clinically, beta-blockers appropriately titrated are 
indicated in patients with STEMI, NSTE-ACS and LV dysfunction 
with or without signs of heart failure [7,8]. In stable coronary 
heart disease (CHD), there is solid evidence to show that BB 
effectively relieve anginal symptoms and improve myocardial 
ischemia, and are therefore recommended as first-line agents 
for symptom relief in both U.S. [9] and European [10] guidelines. 
However, the evidence base for the use of BB to improve 
prognosis in asymptomatic patients, who represent about 
80% of the stable CHD population [11], is less robust and not 
supported by data from an appropriately powered randomized 
trial [12]. Additionally, a recent report from the REACH registry 
has demonstrated that BB usage in patients with stable CHD 
was not associated with a reduced rate of CV death, nonfatal MI, 
nonfatal stroke, hospitalization for an atherothrombotic event, 
or revascularization, even in patients with previous MI [13]. 
While guidelines currently recommend 3 years of BB treatment 
after presentation with acute coronary syndrome (ACS) [9], 
should side effects occur there is no definitive evidence to 
insist on continued treatment citing concerns about needing to 
increase the number of formulations of the pill to allow for dose 
adjustments in order to limit side effects.
The concern about limiting the number of formulations of 
the combination pill is well founded because from a technical 
standpoint there is an almost linear relationship between the 
number of active components in the polypill and the difficulty 
of formulation (Figure 1). The difficulty of formulation relates 
to the different characteristics of each component with respect 
to chemical and physical stability. Combining compounds 
with differing solubility and sensitivity to heat and moisture 
requires significant development time and cost. The dosages 
of the different components of the polypill also complicate 
the development process. The use of certain components in 
very low doses (such as ramipril at 2.5 mg) combined with 
another compound at a much higher dose (such as ASA at 100 
mg) causes technical problems with the analytical methods 
used in purification and bioanalytics. The formulation of a 
combination polypill also has illustrated the potential for drug 
incompatibilities and issues with bioavailability.
The Fuster-CNIC-Ferrer CV Polypill has been developed by 
a technologic platform patented by Ferrer. The combination of 
different active ingredients in a single capsule has been achieved 
avoiding the physico-chemical incompatibilities conserving 
at the same time the biopharmaceutical and pharmacokinetic 
properties of every one of its components (Figure 2).
The combination of atorvastatin, rampiril and acetylsalicylic 
acid (ASA) shows a clear chemical incompatibility between the 
three active ingredients. The employed technology achieves the 
stabilization of all of them inside one single pharmaceutical 
form, a capsule.
At the same time, some of the components show a very 
high pharmacokinetic variability which difficults enormously 
the bioequivalence achievement. The Fuster-CNIC-Ferrer CV 
polypill technology has allowed the administration of a single 
pharmaceutical form to be equivalent to the concomitant 
use of every one of the single active ingredient individually 
administered.
The Fuster-CNIC-Ferrer CV polypill includes ASA (100 mg), 
ramipril (in doses of 2.5, 5, or 10 mg) and Atorvastatin 20 mg.
2. Pharmacological characteristics of Trinomia®
Extensive controlled, randomised studies have demonstrated 
that treatment with the proposed dosages of ASA, atorvastatin, 
and ramipril decrease mortality in patients with established 
CVD [14–16]. There is also extensive experience with the 
combination therapy of these medications in free combinations 
for CV prevention, with an adequate risk/benefit ratio, in clinical 
practice.
2.1. In vivo and in vitro studies with Trinomia®
2.1.1 In vitro: biopharmaceutical studies
A battery of comparative in vitro dissolution studies between 
the biobatch for the fixed-dose combination (test) and the 
reference products for ASA (Aspirine N® 100mg), Ramipril 
10mg (Acovil®), and atorvastatin (Cardyl® 20 mg) used in the 
bioequivalence studies, found that there is a similar in vitro 
dissolution profile between the biobatch and the reference 
products used in the bioequivalence study [17].
2.1.2 In vivo: biopharmaceutical studies: bioequivalence study
Ferrer Internacional, S.A. (Barcelona, Spain) performed a 
randomised, open-label, two-period, two-sequence, controlled, 
cross-over, bioequivalence study of single-dose atorvastatin 20 
mg, ramipril 10 mg, and ASA 100 mg fixed-dose combination 
capsule vs. equivalent doses of Cardyl® 20 mg film-coated 
tablets + Acovil® 10 mg tablets + Aspirin N® 100 mg tablets 
(reference formulations), in order to establish the rate and 
extent of absorption of Trinomia® compared to the individual 
components. The study was carried out under fasting conditions 
(bioequivalence studies in fasting conditions are considered 
Fig. 1. Relationship between the number of drugs in a polypill and the formulation 
challenges, patentability, and clinical value. Adapted from Guglietta A, and 
Guerrero M. (reprinted with permission, license number: 3640791509009).
Fig. 2. The Fuster-CNIC-Ferrer CV Polypill (Trinomia®, Sincronium®, Iltria®) 
technology.
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to be the most sensitive condition to detect a potential 
difference between formulations). Even though there are no 
relevant interactions with food for any of the components, it 
is recommended to take the Fuster-CNIC–Ferrer CV polypill 
after meals in order to improve tolerability mainly related to 
aspirin. In accordance with the Guideline on the Investigation 
of Bioequivalence [18], this study confirms the bioequivalence of 
Trinomia as the geometric 90% confidence intervals for the log-
transformed results of the area under the plasma concentration-
time curve from time 0 to the last sampling time [AUC(0t)] and 
peak plasma concentrations (Cmax) within the acceptable interval 
of 80% to 125% for aspirin, atorvastatin, and ramipril (Table 1). 
Thus, the Fuster-CNIC–Ferrer CV polypill is the first-in-class 
polypill that has been found bioequivalent as compared with the 
individual components of the polypill.
Regarding safety, the results of this bioequivalence study also 
confirmed that there is no difference in tolerance and safety 
between the two treatment groups.
2.2. Pharmacodynamic properties of the components of Trinomia®
Long-term, controlled, randomised studies have demonstrated 
that treatment with the dosages of ASA, atorvastatin, and 
ramipril contained in the Fuster-CNIC-Ferrer CV polypill decrease 
mortality in patients with established CVD. There is also extensive 
experience with the combination therapy of these medications 
in free combinations for CV prevention, with an adequate risk/
benefit ratio, in clinical practice [10].
2.2.1. Ramipril
This angiotensin converting enzyme inhibitor (ACEI) decreases 
plasma and tissular levels of angiotensin II (Figure 3A) [19]. The 
maximum inhibition of plasma ACE activity (>90%) appeared 
within 1–4 hours and persisted inhibited by 80% after 24 hours. 
Epidemiological studies have consistently demonstrated that 
high blood pressure levels correlate with the risk of CVD and 
cerebrovascular accidents [20] and antihypertensive drugs reduce 
the risk of both conditions, not only in hypertensive patients, but 
also in those who have a high CVD risk and normal blood pressure. 
Present ESC guidelines recommend ACEIs in hypertensives with 
LV hypertrophy, HF or LV dysfunction, myocardial infarction (MI), 
diabetes, peripheral artery disease, chronic kidney disease or 
microalbuminuria, metabolic syndrome and atherosclerosis [21]. 
The Heart Outcomes Prevention Evaluation (HOPE) trials showed 
that in high risk patients ≥55 years of age with evidence of CVD 
or diabetes plus a CV risk factor ramipril (10 mg/day over 5 years) 
significantly reduced the rates of death, MI, and cerebrovascular 
accidents [22]. A similar benefit was reproduced in diabetic 
patients. In this study, ramipril also significantly reduced the 
development of HF in patients without known low LV ejection 
fraction or HF and in elderly patients reduced the risk of major 
CV events, CV deaths, MI, and cerebrovascular accidents.
A meta-analysis of the HOPE, the European trial on Reduction 
Of cardiac events with Perindopril among patients with stable 
coronary Artery disease (EUROPA), and the Prevention of Events 
with ACE inhibition (PEACE) trials found that ACEIs significantly 
reduce serious vascular events in patients with atherosclerosis 
without known evidence of HF or LV systolic dysfunction [23]. 
Similarly, ACEIs reduce total mortality and major CV end points 
in patients who have CHD and no LV systolic dysfunction or 
HF [24]. In patients with MI the Acute Infarction Ramipril 
Efficacy (AIRE) Study [15] showed that ramipril produces a 27% 
risk reduction (RR) in mortality compared with placebo. This 
benefit persisted in patients taking aspirin. Interestingly, ACEIs 
were effective when administered with antiplatelet and lipid-
lowering agents. In the Ramipril Efficacy in Nephropathy (REIN) 
trial ramipril reduced the glomerular filtration rate decline more 
than expected from the blood pressure drop [25]. Therefore, 
present AHA/ACC and ESC guidelines recommend ACEIs for all 
patients with an EF £40% to reduce the risk of HF hospitalization 
and the risk of premature death [6,9] and in all patients after an 
ACS in the absence of contraindications [10].
2.2.2. Atorvastatin
This selective and competitive inhibitor of the (3-hydroxy-
3-methyl-glutaryl-CoA (HMG-CoA) reductase reduces the 
hepatic synthesis of cholesterol (Figure 3B). In patients with 
hypercholesterolemia or with mixed hyperlipidemia, ator-
vastatin dose-dependently (10–80 mg daily) decreases total 
cholesterol (30–46%), LDL-C (37–55%), apolipoprotein B (34–
50%) and triglycerides (14–33%) plasma levels, and produces 
variable increases in HDL-C (2–12%) [26].
Statins are effective in the primary prevention and secondary 
prevention of CV diseases [27]. In a meta-analysis of 27 trials 
(n=174,149), a 1 mmol/L (40 mg/dL) reduction in LDL-C levels 
by statin therapy results in a 21% RR in major vascular events 
(MI, coronary death, coronary revascularization, or stroke) and 
a 12% RR in vascular mortality [28]. In the GREek Atorvastatin 
and Coronary-heart-disease Evaluation (GREACE) study, long-
term treatment of CHD with atorvastatin (mean dose 24 mg/day) 
significantly reduced the relative risk, in comparison to usual 
care, of all-cause (RRR 43%), coronary mortality (RRR 47%) and 
morbidity (RRR 54%) and stroke (RRR 47%) [14]. In a cohort study, 
statin therapy produced a 40% RRR in hospitalisation for acute 
MI; the 20 mg daily of atorvastatin was equipotent to 80 mg 
of pravastatin, 160 mg of fluvastatin, and 40 mg of simvastatin 
[29]. Furthermore, early atorvastatin therapy (20 mg/day 
within 48 hours) reduced long-term major adverse cardiac and 
cerebrovascular events (MACCE) as compared with placebo.
(30) A review of 52 clinical studies recommended 20 mg of 
atorvastatin as the standard initial dose in patients requiring a 
LDL-C reduction of 35-50% [31]. In the NICE Guideline 2014 Lipid 
modification [32] a daily 20 mg dose of atorvastatin reduces 
LDL-C to a similar extent (43%) than 10 mg of rosuvastatin and 
80 mg of simvastatin, and more than 40 mg of pravastatin and 
40 mg of simvastatin. This guideline recommends atorvastatin 
20 mg for the primary prevention of CVD to people with or 
without type 2 diabetes who have a 10% or greater 10-year risk of 
developing CVD, for the secondary prevention of CVD to people 
with chronic kidney disease (CKD) and for people ≥85 years to 
reduce the risk of non-fatal MI. Because 20 mg atorvastatin dose 
presents a good overall balance between efficacy and safety, this 
dose was selected for Trinomia®.
Table 1
Results of bioequivalence studies comparing components of the 
Fuster-CNIC-Ferrer CV Polypill to monocomponents
Drug Parameter 90% CI
Acetyl salycilic acid
 AUC0–t 96.92–104.47 BE
 Cmax 84.51–95.78 BE
Ramipril
 AUC0–t 108.13–120.11 BE
 Cmax 91.51–112.62 BE
Atorvastatin
 AUC0–t 95.50–105.93 BE
 Cmax 94.58–116.14 BE
The upper and lower CL (confidence level) demonstrate that the ratio 
and corresponding 90% confidence interval of the relative AUC0-t and Cmax 
geometric least square means of the Test to Reference formulation are in the 
pre-specified 80.00 to 125.00% bioequivalence range for all components of the 
fixed combination.
AUC 0-t area under the curve. Cmax: maximun plasma concentration. CI: 
confidence interval. BE: bioequivalence
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2.2.3. Aspirin
Aspirin inhibits platelet aggregation by irreversibly inhibiting 
the enzyme cyclooxygenase-1 (Figure 3C) and its antiplatelet 
effect last for the duration of platelet life (~10 days) [33]. In 
randomised, controlled trials in patients with one or more major 
CV risk factors or who have suffered a MI have demonstrated the 
efficacy of low-doses of aspirin in the prevention of CV deaths and 
total cerebrovascular accidents [34]. Interestingly, the efficacy of 
low doses of aspirin (up to 325 mg/day) in preventing the risk of 
MI or stroke is greater than with higher doses. A meta-analysis of 
287 randomised trials confirmed that long-term treatment with 
aspirin (75–125 mg/day) for secondary prevention in a wide 
range of patients with high CV risk (patients with a history of MI, 
stroke or transient ischemic attacks, or some major CV events) 
achieved a RRR of 32% in the incidence of new cardiovascular 
events, with no apparent adverse effect on non-cardiovascular 
deaths whereas the RRR for the same outcomes was a 26% for 
the dose range from 160–325 mg and only of 19% with doses 
ranging from 500 mg to 1500 mg [35]. Because of its favorable 
benefit-risk ratio, lifelong low-doses of aspirin (75–125 mg) are 
the cornerstone for the secondary prevention of MI and death in 
patients with coronary artery disease and other atherosclerotic 
cardiovascular disease unless contraindicated [6,9,36].
The Fuster-CNIC-Ferrer CV polypill contains 100 mg of ASA, 
dose included in the most favourable recommended dosage 
range by the current prevention guidelines [6].
2.3. Pharmacokinetic properties of the components of 
Fuster-CNIC-Ferrer CV Polypill (Table 2)
2.3.1. Ramipril
It is rapidly absorbed, reaching peak plasma concentrations 
(Cmax) within 1 h. The rate, but not the extent, of absorption 
is delayed with food.(19) Ramipril is almost completely 
biotransformed in the gut wall and the liver into its metabolite 
ramiprilat, which has about 6 times the ACE inhibitory activity 
of ramipril and reaches its Cmax within 2–4 h and steady-state 
plasma levels after 4 days. The Cmax and the 24-hour AUC for 
ramiprilat are linear at doses of ramipril between 2.5 and 10 mg 
[37]. Ramipril and ramiprilat bind to plasma proteins and are 
widely distributed, reaching higher concentrations in kidneys 
and lungs than in blood [37]. Ramipril and its metabolites are 
excreted in urine (60%, but <2% as unchanged ramipril) and 
faeces. After multiple daily doses of 5 and 10 mg of ramipril, the 
half-life of ramiprilat is 13–17 hours. ACEIs can cause fetal and 
neonatal morbidity and death when given to pregnant women 
(Pregnancy Category D). There is no information on the use of 
ramipril during breastfeeding.
2.3.2. Atorvastatin
It is rapidly orally absorbed, but presents low oral bioavailability 
due to high pre-systemic clearance. Food can decrease the rate 
and extent of drug absorption, but does not modify the reduction 
Fig. 3. Mechanism of action of (A) ramipril, (B) atorvastatin and (C) acetylsalicilic acid. ACE: angiotensin-converting enzyme. COX: cyclo-oxigenase. ET-1: endothelin-1. GI: 
gastrointestinal. NO: nitric oxide. ROS: reactive oxygen species. PGs: prostaglandins. PP: pyrophosphate.
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on LDL-C. Atorvastatin highly binds to plasma proteins and 
presents a large volume of distribution; thus, hemodialysis does 
not increase drug clearance [38]. Atorvastatin is a substrate of 
the hepatic uptake transporter OATP1B1 and is predominantly 
metabolised by cytochrome P450 3A4 (CYP3A4) into metabolites 
that are responsible for 70% of its LDL-C lowering effects, undergo 
further metabolism via glucuronidation and are eliminated in 
bile. The Cmax and AUC of atorvastatin are 4- and 11-fold greater 
in patients with Childs-Pugh A and B disease, respectively. Thus, 
Fuster-CNIC-Ferrer CV Polypill® is contraindicated in patients 
with severe liver failure. Conversely, since <2% of the dose is 
excreted in urine, dose adjustment are not necessary in patients 
with mild-moderate CKD [39]. The half-life of atorvastatin is 
~14 hours, but the half-life of the inhibitory activity for HMG-
CoA reductase is 20-30 hours due to its active metabolites. This 
explains why LDL-C reduction is the same regardless the time 
the drug is administered. Atorvastatin use is contraindicated in 
pregnancy (Pregnacy Category X), but it is unknown whether the 
drug or its metabolites are excreted in human breast milk [19].
2.3.3. Aspirin
It is rapidly and almost completely absorbed in the stomach 
and small intestine [41], reaches the Cmax within 15–20 minutes 
and platelet function is inhibited within 1 hour. Aspirin is 
rapidly biotransformed by plasma and tissular esterases into 
salicylic acid being undetectable 1–2 h after dosing (half-life 
~15–20 min). Salicylic acid reaches the Cmax within 1–2 h, binds 
to plasma proteins (90–99%) and is widely distributed to all 
tissues, crosses the blood-brain barrier and the placenta and is 
excreted into breast milk. At low doses (<250 mg), salicylic acid is 
glucoconjugated in the liver with glycin (salicyluric acid) and to 
a lesser extent with glucuronic acid and presents an elimination 
half-life of 2–4 hours [60]. Salicylic acid is excreted mainly in 
urine, but its urinary excretion increases 10–20 times (from 5% 
to more than 80%) when urine pH rises from 5 to 8 [42]. Pregnant 
women (Pregnacy Category D) and those breastfeeding should 
avoid taking aspirin unless specifically advised by their doctor.
2.4. Safety of the components of Fuster-CNIC-Ferrer CV Polypill
Acetylsalicylic acid, atorvastatin, and ramipril have been 
marketed at the proposed dosages worldwide for decades, 
with an established safety profile, and are available as generic 
products. This extensive, long-term use of the three drugs in 
clinical practice provides a large patient population for analysing 
the safety of these three drugs. On the other hand, the dosage 
regimen proposed for this polypill (once per day) is the same 
as for all of the active components. Therefore, it is not expected 
that changing from the concurrent use of the three individual 
pills in free combination to the polypill will result in a potentially 
different safety profile.
2.4.1. Ramipril
Adverse effects are mild and transient, and drug dis con-
tinuation due to AEs effects is observed in 3% of patients. 
The most common AEs include hypotension, dry cough, 
dizziness, headache, asthenia, nausea and gastrointestinal (GI) 
disturbances [43]. Other AEs include a decrease in hemoglobin 
or hematocrit, dermatological reactions (rash, urticaria, pruritus, 
photosensitivity), neurologic reactions (headaches, blurred 
vision) and impotence. Because ramipril decreases aldosterone 
release, hyperkalemia can occur, particularly in patients with 
renal failure.
Hypotension can be observed at the beginning of the treat-
ment, particularly in patients with HF post-MI, renal artery 
stenosis, hyponatremia, hypovolemia or increased serum 
creatinine (1.5–3 mg/dL or 135–265 mol/L). Ramipril produces 
a preferential vasodilatation of glomerular efferent arterioles, 
reduces the intraglomerular pressure and may increase serum 
creatine levels at the beginning of treatment in patients with 
hypotension, hyponatremia or renal insufficiency and in 
hypertensive patients with unilateral or bilateral renal artery 
stenosis. ACEIs can produce angioedema, particularly in blacks; 
warning signs include facial swelling, unilateral facial or 
periorbital oedema [44].
2.4.2. Atorvastatin
The most frequently described AEs are GI (anorexia, nausea, 
flatulence, and constipation), headache, skin rashes, dizziness, 
blurred vision, insomnia, and dysgeusia [45]. Myopathy, 
characterised by myalgia and muscle weakness with increased 
levels of creatine phosphokinase (CPK) >10 times the upper 
limit of normal (ULN) has been reported, especially in patients 
treated potent CYP3A4 inhibitors, cyclosporine, fibrates or 
niacin (Table S1) [46,47]. Rhabdomyolysis is a very rare AE 
(~1 per 100,000 patient-years); if suspected or diagnosed, 
Table 2
Pharmacokinetic profile of the components of the Fuster-CNIC-Ferrer CV Polypill
Drug Atorvastatin Aspirin Ramipril
Bioavailability (%) 14 68 Ramipril - 28
 (30 metabolites)  Ramiprilat - 44
Cmax (h) 1–2 0.25–0.3 Ramipril - 0.1–1
   Ramiprilat - 2–4
Tmax (h) 5–7 0.33 Ramipril - 1–2
  1–2 (salycilic acid) Ramiprilat - 3.0
PPB (%) ≥98 99 (salycilic acid) Ramipril - 73
   Ramiprilat - 56
Vd (L/kg) 5.4 0.15 -
Metabolism Hepatic CYP450 3A4 Hepatic (multiple) Hepatic hydrolysis
Active metabolites yes yes Ramiprilat
Half-life (h) 14 15-20 min Ramipril - 5
  2-4 h (low doses) Ramiprilat - 13-17 
Excretion (%) Renal – 2 Renal – 5 Renal - 60
 Feces - 98 Depend on urinary pH Feces - 40
Breast milk yes yes no
Abbreviations: Cmax: peak plasma drug concentrations. h: horas. PPB: plasma protein binding. Tmax: time to reach peak plasma levels or Cmax. Vd. Volume of 
distribution
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atorvastatin should be discontinued immediately. Transaminase 
elevations >3 times ULN occurs in 0.2%, 0.2%, 0.6% of patients 
treated with atorvastatin 10, 20 and 40 mg, but serious liver 
injury rarely occurs. Other reported AEs include amnesia, 
increased weight, nightmares, paresthesia, peripheral edema 
and thrombocytopenia. New-onset diabetes has been reported, 
but the risk is low both in absolute terms and when compared 
with the reduction in coronary events [48]. Treatment with 
statins for 4 years resulted in 1 extra case of diabetes, whereas 
5.4 coronary events (coronary death, non-fatal MI) are prevented 
[49]. In postmarketing studies, rare and reversible AEs, 
including hepatitis, pancreatitis, depression, bullous rashes and 
hypersensitivity reactions, have been reported.
2.4.3. Aspirin
The most common AEs are GI (dyspepsia, nausea, and 
diarrhea). (46) These AEs are usually mild, although in patients 
a peptic ulcer severe GI hemorrhage may occur [50]. Aspirin 
increases major (hemorraghic stroke) and minor bleeding 
(epistaxis, hematuria, melena, bruising), but when used in 
secondary prevention, the balance clearly favors benefit. In a 
meta-analysis, aspirin (75–325 mg/day) increased the risk of 
major GI bleeding and intracranial bleeding versus placebo [51], 
but 769 patients (95% CI 500–1250) need to be treated to cause 
1 additional major bleeding episode annually. The risk of GI 
bleeding increases when aspirin is co-administered with other 
NSAIDs, antiaggregants or anticoagulants [52]. In patients at 
increased risk of GI bleeding, a proton pump inhibitor should be 
used.
Others adverse effects include weakness, dizziness, tinnitus, 
edema, hyperkalemia and deterioration of renal function. Allergic 
responses (anaphylactic shock, skin rash, asthma) are rare 
(<0.5%), but aspirin may precipitate bronchospasm in patients 
with asthma or NSAID-precipitated bronchospasm. Aspirin has 
been implicated in some cases of Reye syndrome, so it should not 
be prescribed in children and adolescents under 18 years of age.
In recent decades, there has been concurrent use worldwide 
of the three drugs for secondary prevention of CVD as a 
free combination, which has provided solid evidence on the 
appropriate risk/benefit ratio. This drug combination has not 
been associated with an increased incidence of adverse effects.
The conclusions of the fixed-dose combination safety study 
carried out by Yusuf et al. with Polycap with five components, 
although carried out in primary prevention, confirmed that the 
safety of the fixed-dose combination was similar to treatment 
with each drug in monotherapy. The study found there were no 
increases in adverse events specific to the drug [53].
The recent published FOCUS study with a polypill contain-
ing asprin, simvastatin and ramipril compared to the 
monocomponents in 695 post MI patients also confirmed that 
there were no differences in the occurrence of adverse events 
between both groups whereas the polypill treated group showed 
a significantly greater adherence rate compared to the control 
group after 9 months of follow up [4].
2.5. Drug Interactions
The main drug interactions of ramipril, atorvastatin and 
aspirin are summarized in Additional file 1 (Table S1).
A potential interaction between ACEIs and aspirin was 
proposed as aspirin inhibits prostaglandin synthesis and causes 
sodium and water retention which might potentially counteract 
the blood pressure lowering effects of ramipril. However, the 
evidence of this potential interaction came from clinical trials 
not designed to examine this issue [54]. Indeed, several studies 
and two meta-analysis confirmed the efficacy and safety of ACEIs 
in patients treated with aspirin [55,56]. A meta-analysis of 6 
long-term trials (22,060 patients) found that ACEIs significantly 
reduced the risk of the major clinical outcomes, both among 
in patients receiving (OR 0.80, 99% CI 0.73–0.88) or not aspirin 
at baseline (0.71, 99% CI 0.62–0.81) [57]. In 96,712 patients 
allocated to receive ACEIs or standard therapy in the acute phase 
of MI (0–36 h from onset), ACEI therapy was associated with 
similar reductions in 30-day mortality, irrespective of whether 
or not aspirin was given [58]. Furthermore, in patients with CAD 
and diagnosis of HF, the use of aspirin in conjunction with ACEIs 
does not worsen long-term survival compared to the use of ACEIs 
without aspirin [55]. Thus, there is no evidence of a decreased 
efficacy of ACEIs when coadministered with low doses of aspirin 
(up to 200 mg).
Interestingly, a synergy between statins and ACEIs has been 
suggested [59]. In a post hoc analysis of the GREek Atorvastatin 
and Coronary-heart-disease Evaluation (GREACE) trial in 
high-risk patients with CAD treatment with statins and ACEIs 
significantly reduced the cardiovascular events (all-cause and 
coronary mortality, nonfatal MI and stroke) more than statins 
alone and considerably more than ACEIs alone [60]. Moreover, 
in the HOPE trial the benefit of ramipril was observed in patients 
already treated with aspirin, beta-blockers, and statins [22].
2.6. Posology
The Fuster-CNIC-Ferrer CV Polypill should be administered 
once daily, preferably after food and accompanied by liquid to 
reduce the risk of GI effects caused by the aspirin. The capsules 
should not be opened, chewed, or crushed. For the prevention 
of CV events, the recommended maintenance dose of ramipril 
is 10 mg daily. In elderly patients, treatment should be initiated 
with precaution due to the higher risk of adverse effects. In 
patients with CKD the daily dose of Fuster-CNIC-Ferrer CV 
Polypill should be based on creatinine clearance (crCl). When 
the crCl is ≥60 mL/min, the maximum daily dose of ramipril 
is 10 mg, if crCl is 30-60 mL/min the maximum daily dose of 
ramipril is 5 mg, but the Fuster-CNIC-Ferrer CV Polypillis 
contraindicated in patients in hemodialysis or with severe 
kidney failure (CrCl <30 mL/min) (Table 3) [16]. Liver function 
tests should be carried out in patients with liver disease before 
beginning treatment with the Fuster-CNIC-Ferrer CV Polypill and 
periodically afterwards. Patients who developed increased levels 
of transaminases should be monitored until the abnormality 
is resolved and the Fuster-CNIC-Ferrer CV Polypill should be 
discontinued if the increase in transaminase is >3× the ULN. The 
maximum daily dose of ramipril in this patient group is 2.5 mg.
2.7 . Contraindications
The main contraindications of the Fuster-CNIC-Ferrer CV 
Polypill are a compilation of the ones described in the summary 
of product characteristics of each of the single components and 
are summarized in Table 3. The Fuster-CNIC-Ferrer CV Polypill 
is therefore contraindicated in women who are pregnant, trying 
to become pregnant, or suspected to be pregnant because it can 
produce teratogenic effects [19]. It should also be avoided during 
lactation as small amounts of statins and aspirin are found in the 
mother’s milk and is contraindicated in children and adolescents 
under 18 years of age [16].
3. Fuster-CNIC-Ferrer CV polypill marketing authorization
The Fuster-CNIC-Ferrer CV Polypill (Trinomia®, Sincronium®, 
Iltria®) including aspirin (100 mg), ramipril (in doses of 2.5, 5, 
or 10 mg to allow for titration) and atorvastatin 20 mg has been 
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approved at present by the Medicine Agencies of 15 European 
countries (Austria, Belgium, Bulgaria, Czech Republic, Finland, 
France, Germany, Greece, Ireland, Italy, Poland, Portugal, 
Rumania, Spain, Sweden) and Chile for its use in secondary 
prevention of CV events. The indication for its use is for the 
secondary prevention of CV events as substitution therapy in 
adult patients adequately controlled with the monocomponents 
given concomitantly at equivalent therapeutic dosages [13]. 
Currently it has been marketed in Spain, Portugal, Romania 
and Germany under two different brand names: Trinomia® and 
Sincronium®.
During the next years, it has been planned to launch the 
Fuster-CNIC-Ferrer CV polypill in additional European countries 
as well as worldwide.
4. Conclusions
The concept of a pill containing guideline recommended 
therapy for secondary prevention, composed of aspirin, an 
antihypertensive agent and a statin has been suggested for over 
a decade to simplify treatment complexity, increase accessibility 
to treatment and serve as a cost effective public health 
strategy to improve pharmacological treatment worldwide. 
In stark contrast to the simple concept of the cardiovascular 
polypill itself (including three active principles in one pill) the 
pharmacological development of such a strategy has proven to 
be extremely complex from a formulation point of view. The 
Fuster-CNIC-Ferrer CV Polypill has made the leap from this 
conceptual debate to clinical reality and has become first in class 
to achieve bioequivalence of all components, which in turn has 
led to widespread approval by regulatory agencies.
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Table S1
Drug interactions of the components of the Fuster-CNIC-Ferrer CV Polypill (Trinomia®, Sincronium®, Iltria®)
Interacting drug(s) PD/PK consequence Clinical implications
Ramipril
• Antihypertensives





Increase the antihypertensive response of 
ramipril
Monitor blood pressure
ARBs, Beta-blockers, Heparin, K+-sparing diuretics, K+ 
supplements, Tacrolimus, Trimethoprim.
Increase the risk of hyperkalemia Monitor plasma potassium levels
Cyclosporine, NSAIDs, Vasopressor sympathomimetics Inhibit the antihypertensive response of ramipril Monitor blood pressure
NSAIDs May produce renal failure in the elderly or 
dehydrated patients
Lithium salts Decreases lithium renal excretion and increases 
plasma levels and toxicity. 
Monitor lithium plasma levels
Oral antidiabetic agents or insulin Increase the risk of hypoglycaemia Monitor glucose plasma levels
Erythropoietin Higher doses of erythropoietin are needed in 
dialysed patients
Aliskiren, ARBs Increased renal dysfunction Avoid the combination
Drugs eliminated by the kidney:
• Atenolol, Flecainide, Disopyramide, Nadolol, 
Procainamide, Sotalol,
Ramipril decreases their renal clearance Monitor drug response
Temsirolimus Increased risk for angioedema With caution
Atorvastatin
Strong CYP3A4 inhibitors:
• Azole antifungals (Itraconazole, Ketoconazole, 
Posoconazole, Voriconazole),
• Clarithromycin, Telithromycin
• HIV-protease inhibitors: Atazanavir, Darunavir, 
Fosamprenavir, Indinavir, Lopinavir, Nelfinavir, 
Ripanavir, Ritonavir, Saquinavir, Tipranavir
• Hepatitis C protease inhibitors: telaprevir
• Other: Ciclosporin, Delavirdine, Stiripentol
Significantly increased the Cmax of atorvastatin 
and the risk of myopathy
Atorvastatin should be used with caution and close 
clinical monitoring is recommended.
Clarithromycin, itraconazole: caution at doses 
>20 mg/day
HIV protease inhibitors: should be avoided if 




• Amiodarone, Erythromycin, Fluconazole, Fluoxetine, 
Grapefruit juice, Lomipatide, Verapamil
They may increase the Cmax of atorvastatin and 
the risk of myopathy. 
Starting dose: 10 mg/day   
Ezetimibe, Fibrates, Fusidic acid, Gemfibrozil, Niacin Increased risk of myopathy and rabdomyolysis Avoid combination with gemfibrozil. Clinical 
monitoring is recommended
CYP3A4 inducers:
• Carbamazepin, Eferivenz, Rifampin, St. John’s wort
Variable decrease in the plasma concentrations of 
atorvastatin 
OATP1B1 inhibitors: Cyclosporine It increases the C
max
 of atorvastatin Monitor clinical efficacy
Digoxin Plasma digoxin levels increase (20%) Monitor digoxin plasma levels
Colchicine Cases of myopathy and rhabdomyolysis, have 
been reported
Caution when prescribing atorvastatin with 
colchicine.
Oral contraceptives Increased AUC values for norethindrone and 
ethinyl estradiol








• Selective serotonin and serotonin-norepinephrine 
reuptake inhibitors
• Tositumomab
The risk of GI ulcers and bleeding increases Monitor for signs of external or internal bleeding
ACEIs, ARBs, beta-blockers, thiazides Aspirin can decrease their antihypertensive 
effects 
Monitor blood pressure
Antiacids Increase the renal excretion of aspirin Monitor drug response
COX-1 inhibitors: ibuprofen, naproxen) Can prevent the antiaggregant and 
cardioprotective effects of aspirin 
Avoid the combination
Ciclosporine NSAIDs may increase the nephrotoxicity of 
ciclosporine
Careful monitoring of renal function
Digoxin Plasma digoxin levels increase (20%) Monitor digoxin plasma levels
Diuretics NSAIDs can cause acute renal failure in 
dehydrated patients
Monitor hydratation of the patient
Methotrexate, tacrolimus Aspirin displace these drugs from plasma 
proteins and decrease their renal excretion
Dose adjustment or more frequent monitoring of 
renal function and hemogram
Oral antidiabetic agents or insulin Increase the risk of hypoglycaemia Monitor glucose plasma levels
Uric acid Aspirin inhibits kidneys’ ability to excrete uric 
acid and reduce the effect of uricosuric drugs
With caution in patients with hyperuricemia, or 
gout
Barbiturates, Lithium salts, Phenytoin, Zidovudine Aspirin increases their plasma levels. It decreases 
the renal excretion of lithium 
Monitor the patient’s response. Monitor plasma 
lithium levels
Abbreviations: ACEIs: angiotensin converting enzyme inhibitors. ARBs: angiotensin receptor blockers. AUC: area under the plasma drug concentration-time 
curve. Cmax: peak plasma concewntrations. COX: cyclooxygenase. GI: gastrointestinal. NSAIDs. Non-steroidal anti-inflammatory drugs. OATP1B1: organic anion-
transporting polypeptide 1B1. PD/PK: pharmacodynamic/pharmacokinetic.
